Skip to main content
PMC home page
Gut logoLink to Gut
. 1976 May;17(5):341–344. doi: 10.1136/gut.17.5.341

Altered elimination of antipyrine in patients with acute viral hepatitis.

D A Burnett, A J Barak, D J Tuma, M F Sorrell
PMCID: PMC1411129  PMID: 1278717

Abstract

The plasma half-life and clearance of antipyrine was investigated in patients during the acute phase and again during the recovery phase of viral hepatitis. Each patient served as his own control, thereby eliminating genetic factors and minimising environmental factors that cause large interindividual variations in antipyrine elimination rates. Liver function tests, antipyrine, half-life, plasma clearance, and the apparent volume of distribution were determined in the acute and recovery period. It was found that the appaarent volume of distribution of antipyrine did not change in five of six patients as they recovered. Five of the six patients showed prolonged plasma half-lives and decreased plasma clearance of the drug at the time of acute illness and these parameters reached normal values during recovery. The plasma half-life and clearance of the drug did not correlate with biochemical indices of liver function in the recovery phase. This demonstration supports the concept that drug metabolism is frequently impaired in liver disease.

Full text

PDF
341

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andreasen P. B., Ranek L., Statland B. E., Tygstrup N. Clearance of antipyrine-dependence of quantitative liver function. Eur J Clin Invest. 1974 Apr;4(2):129–134. doi: 10.1111/j.1365-2362.1974.tb00383.x. [DOI] [PubMed] [Google Scholar]
  2. BRODIE B. B., AXELROD J. The fate of antipyrine in man. J Pharmacol Exp Ther. 1950 Jan;98(1):97–104. [PubMed] [Google Scholar]
  3. BRODIE B. B., BURNS J. J., WEINER M. Metabolism of drugs in subjects with Laennec's cirrhosis. Med Exp Int J Exp Med. 1959;1:290–292. doi: 10.1159/000134806. [DOI] [PubMed] [Google Scholar]
  4. Davies D. S., Thorgeirsson S. S. Mechanism of hepatic drug oxidation and its relationship to individual differences in rates of oxidation in man. Ann N Y Acad Sci. 1971 Jul 6;179:411–420. doi: 10.1111/j.1749-6632.1971.tb46918.x. [DOI] [PubMed] [Google Scholar]
  5. Doshi J., Luisada-Opper A., Leevy C. M. Microsomal pentobarbital hydroxylase activity in acute viral hepatitis. Proc Soc Exp Biol Med. 1972 Jun;140(2):492–495. doi: 10.3181/00379727-140-36487. [DOI] [PubMed] [Google Scholar]
  6. Hoffman T. A., Cestero R., Bullock W. E. Pharmacodynamics of carbenicillin in hepatic and renal failure. Ann Intern Med. 1970 Aug;73(2):173–178. doi: 10.7326/0003-4819-73-2-173. [DOI] [PubMed] [Google Scholar]
  7. Huffman D. H., Shoeman D. W., Azarnoff D. L. Correlation of the plasma elimination of antipyrine and the appearance of 4-hydroxy antipyrine in the urine of man. Biochem Pharmacol. 1974 Jan 15;23(2):197–201. doi: 10.1016/0006-2952(74)90410-9. [DOI] [PubMed] [Google Scholar]
  8. Klotz U., Avant G. R., Hoyumpa A., Schenker S., Wilkinson G. R. The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J Clin Invest. 1975 Feb;55(2):347–359. doi: 10.1172/JCI107938. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Klotz U., McHorse T. S., Wilkinson G. R., Schenker S. The effect of cirrhosis on the disposition and elimination of meperidine in man. Clin Pharmacol Ther. 1974 Oct;16(4):667–675. doi: 10.1002/cpt1974164667. [DOI] [PubMed] [Google Scholar]
  10. Levi A. J., Sherlock S., Walker D. Phenylbutazone and isoniazid metabolism in patients with liver disease in relation to previous drug therapy. Lancet. 1968 Jun 15;1(7555):1275–1279. doi: 10.1016/s0140-6736(68)92292-7. [DOI] [PubMed] [Google Scholar]
  11. MARCUS F. I., KAPADIA G. G. THE METABOLISM OF TRITIATED DIGOXIN IN CIRRHOTIC PATIENTS. Gastroenterology. 1964 Nov;47:517–524. [PubMed] [Google Scholar]
  12. Mawer G. E., Miller N. E., Turnberg L. A. Metabolism of amylobarbitone in patients with chronic liver disease. Br J Pharmacol. 1972 Mar;44(3):549–560. doi: 10.1111/j.1476-5381.1972.tb07292.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Maxwell J. D., Carrella M., Parkes J. D., Williams R., Mould G. P., Curry S. H. Plasma disappearance and cerebral effects of chlorpromazine in cirrhosis. Clin Sci. 1972 Aug;43(2):143–151. doi: 10.1042/cs0430143. [DOI] [PubMed] [Google Scholar]
  14. McHorse T. S., Wilkinson G. R., Johnson R. F., Schenker S. Effect of acute viral hepatitis in man on the disposition and elimination of meperidine. Gastroenterology. 1975 Apr;68(4 Pt 1):775–780. [PubMed] [Google Scholar]
  15. NELSON E. RATE OF METABOLISM OF TOLBUTAMIDE IN TEST SUBJECTS WITH LIVER DISEASE OR WITH IMPAIRED RENAL FUNCTION. Am J Med Sci. 1964 Dec;248:657–659. doi: 10.1097/00000441-196412000-00004. [DOI] [PubMed] [Google Scholar]
  16. Powell L. W., Axelsen E. Corticosteroids in liver disease: studies on the biological conversion of prednisone to prednisolone and plasma protein binding. Gut. 1972 Sep;13(9):690–696. doi: 10.1136/gut.13.9.690. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Rowland M. Application of clearance concepts to some literature data on drug metabolism in the isolated perfused liver preparation and in vivo. Eur J Pharmacol. 1972 Mar;17(3):352–356. doi: 10.1016/0014-2999(72)90115-x. [DOI] [PubMed] [Google Scholar]
  18. Schoene B., Fleischmann R. A., Remmer H., von Oldershausen H. F. Determination of drug metabolizing enzymes in needle biopsies of human liver. Eur J Clin Pharmacol. 1972 Mar;4(2):65–73. doi: 10.1007/BF00562499. [DOI] [PubMed] [Google Scholar]
  19. Thomson P. D., Melmon K. L., Richardson J. A., Cohn K., Steinbrunn W., Cudihee R., Rowland M. Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans. Ann Intern Med. 1973 Apr;78(4):499–508. doi: 10.7326/0003-4819-78-4-499. [DOI] [PubMed] [Google Scholar]
  20. Vesell E. S., Lee C. J., Passananti G. T., Shively C. A. Relationship between plasma antipyrine half-lives and hepatic microsomal drug metabolism in dogs. Pharmacology. 1973;10(6):317–328. doi: 10.1159/000136453. [DOI] [PubMed] [Google Scholar]
  21. Vesell E. S., Page J. G. Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in man. J Clin Invest. 1969 Dec;48(12):2202–2209. doi: 10.1172/JCI106186. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. WEINER M., CHENKIN T., BURNS J. J. Observations on the metabolic transformation and effects of phenylbutazone in subjects with hepatic disease. Am J Med Sci. 1954 Jul;228(1):36–39. doi: 10.1097/00000441-195407000-00004. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES